Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Iba1-Positive Macrophages and B7-H3-Positive Tumor Cells with Tumor Growth Kinetics in WHO Grade II Meningioma: A Pilot Watch-and-Wait Cohort Study.

Cancers·2026
Same author

Paquinimod Targeting of the S100A8/A9 Axis Suppresses Liver Metastasis in Aged Mice.

Cancers·2026
Same author

Short- and long-term dynamics of gut microbiota, highlighting Fusobacterium nucleatum, Parvimonas micra, and Peptostreptococcus stomatis after colorectal cancer resection: prospective cohort study.

BJS open·2026
Same author

Pre-existing Gut Microbiome Dysbiosis Exacerbates Neuroinflammation and Vasospasm After Subarachnoid Hemorrhage in Mice.

Neurosurgery·2026
Same author

Dual inhibition of xCT and GGCT induces ferroptosis in glioblastoma cells by depleting cysteine and disrupting redox homeostasis.

Cell death discovery·2026
Same author

Beyond tumor mutational burden: a framework for immune-checkpoint blockade responsiveness in gastrointestinal cancers.

International journal of clinical oncology·2026

Related Experiment Video

Updated: Jan 10, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.1K

CAR-T Cell Therapy for Central Nervous System Tumors.

Masasuke Ohno1, Mitsugu Fujita2

  • 1Department of Neurosurgery, Aichi Cancer Center, Nagoya, Japan. m.ono@aichi-cc.jp.

Methods in Molecular Biology (Clifton, N.J.)
|November 22, 2025
PubMed
Summary

Chimeric antigen receptor (CAR) T cell therapy shows promise for brain tumors. Strategies are evolving to overcome the blood-brain barrier and immunosuppressive tumor microenvironment for better CAR T cell efficacy.

Keywords:
Blood–brain barrierCentral nervous system tumorsChimeric antigen receptor T cell therapyGlioblastomaLentiviral vectorsTumor microenvironment

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

716

Related Experiment Videos

Last Updated: Jan 10, 2026

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

4.1K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

716

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR) T cell therapy is a rapidly advancing immunotherapy.
  • Central nervous system (CNS) tumors present unique challenges including the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment (TME).
  • Overcoming these barriers is crucial for effective CAR T cell treatment of CNS tumors.

Purpose of the Study:

  • To review the advancements in CAR T cell therapy for CNS tumors.
  • To discuss the evolution of CAR designs and gene delivery methods.
  • To highlight strategies for overcoming biological barriers in CNS tumor treatment.

Main Methods:

  • Comprehensive literature review of CAR T cell therapy in CNS tumors.
  • Analysis of CAR design evolution, including lentiviral vector (LVV) gene delivery.
  • Examination of clinical applications and challenges.

Main Results:

  • CAR T cell therapy holds significant potential for treating CNS tumors.
  • Lentiviral vectors are key for gene delivery in CAR T cell development.
  • Current strategies focus on enhancing CAR T cell function within the CNS.

Conclusions:

  • CAR T cell therapy is a promising frontier for CNS tumor immunotherapy.
  • Novel CAR designs and delivery methods are essential to address BBB and TME challenges.
  • Continued research is vital to optimize CAR T cell efficacy in the brain.